AbbVie Résultats passés
Passé contrôle des critères 0/6
Les bénéfices de AbbVie ont diminué à un taux annuel moyen de -21%, tandis que le secteur Biotechs a vu ses bénéfices augmenter de en à 37.7% par an. Les revenus ont augmenté de en à un taux moyen de 2% par an.
Informations clés
-20.99%
Taux de croissance des bénéfices
-21.03%
Taux de croissance du BPA
| Biotechs Croissance de l'industrie | 17.04% |
| Taux de croissance des recettes | 2.00% |
| Rendement des fonds propres | n/a |
| Marge nette | 5.72% |
| Prochaine mise à jour des résultats | 31 Jul 2026 |
Mises à jour récentes des performances passées
Recent updates
Mise à jour du récit • Jul 24
ABBV: Future Returns Will Rely On Apogee Deal And Broader Pipeline Execution
AbbVie’s updated analyst price target has increased to $266.89 from $259.46 as analysts factor in recent Q2 preview research, higher modeled profit margins, and a slightly adjusted discount rate and future P/E outlook. Analyst Commentary Recent research commentary around AbbVie points to a broadly constructive tone ahead of Q2 results, with several firms revisiting their models, adjusting P/E assumptions, and updating margin and pipeline expectations.Seeking Alpha • Jul 23
AbbVie: Bright Future, But Already Priced In
Summary AbbVie Inc. remains rated 'Hold' as the stock appears slightly overvalued, with high debt levels tempering further upside. Q1/26 results showed 12.4% revenue growth and 155% free cash flow growth, but GAAP EPS declined 45.8% while adjusted EPS rose 7.7%. ABBV's growth is driven by Skyrizi and Rinvoq (44% of revenue), with Neuroscience and the Apogee Therapeutics acquisition adding pipeline diversification. High leverage from acquisitions may constrain capital allocation, while ABBV's dependency on two drugs and elevated valuation limit near-term attractiveness. Read the full article on Seeking AlphaMise à jour du récit • Jul 10
ABBV: Future Returns Will Depend On Apogee Deal And Broader Immunology Expansion
AbbVie’s refreshed analyst price target framework edges higher to about $259 from roughly $254, with analysts pointing to updated Q2 models, recent target hikes across several firms, and added confidence around the Apogee acquisition’s immunology and respiratory potential as key supports for the revision. Analyst Commentary Recent research on AbbVie centers on two main themes, the refreshed Q2 earnings models and the planned Apogee Therapeutics acquisition.Mise à jour du récit • Jun 23
ABBV: Future Returns Will Hinge On Apogee Deal And Immunology Pipeline
Analysts have made only a modest adjustment to AbbVie’s fair value narrative, reflecting a slightly higher discount rate and updated views on margins and long term P/E in light of the proposed $10.9 billion Apogee Therapeutics deal and its implications for competition and atopic dermatitis market potential. Analyst Commentary Recent research on AbbVie around the proposed US$10.9b Apogee Therapeutics acquisition highlights a mix of optimism about growth opportunities in immunology and atopic dermatitis, alongside caution about execution risk, competition, and valuation.Article d’analyse • Jun 16
AbbVie (ABBV) Stock Could Be 12.6% Undervalued After CLL14 Trial Update
AbbVie (ABBV) is back in focus after releasing nine year final results from its Phase 3 CLL14 trial, where a fixed duration venetoclax plus obinutuzumab regimen improved progression free survival in untreated CLL patients. See our latest analysis for AbbVie. The latest CLL14 update lands after a mixed few sessions for AbbVie, with the share price slipping 2.7% on the day to $221.59, while still showing a 5.3% 30 day share price return and a 19.9% one year total shareholder return that points...Mise à jour du récit • Jun 06
ABBV: Future Returns Will Depend On Expanding Immunology And IBD Pipeline Execution
AbbVie’s updated analyst price target edges higher to $253.55 from $249.43 as analysts factor in slightly higher profit margin assumptions, modestly lower revenue growth expectations, a reduced discount rate, and a somewhat lower future P/E multiple, with recent research highlighting the depth of the inflammatory bowel disease pipeline and broader R&D optionality. Analyst Commentary Recent Street research on AbbVie shows a mix of optimism and caution, with multiple price target revisions clustered within a relatively tight range and commentary that keeps attention on the inflammatory bowel disease pipeline and broader R&D portfolio.Article d’analyse • May 15
We Think You Can Look Beyond AbbVie's (NYSE:ABBV) Lackluster Earnings
The market was pleased with the recent earnings report from AbbVie Inc. ( NYSE:ABBV ), despite the profit numbers being...Mise à jour du récit • Apr 23
ABBV: Future Returns Will Rely On Immunology Expansion And Operating Leverage Execution
Analysts made a small upward adjustment to AbbVie’s fair value estimate to about $249. The modest change reflects a mix of slightly higher assumed discount rates and future P/E multiples, alongside recent shifts in Street price targets, including both raises and trims from firms such as Piper Sandler, Guggenheim, Cantor Fitzgerald, Evercore ISI, Citi and UBS, as well as fresh bullish initiations from Canaccord, RBC Capital and Barclays.Mise à jour du récit • Apr 08
ABBV: Future Returns Will Hinge On Immunology Encore And Operating Leverage Execution
Analysts have made a modest upward adjustment to AbbVie’s price target, reflecting updated views on its immunology pipeline potential, operating leverage, and the ongoing debate about whether recent share underperformance and selloffs adequately reflect competitive risks. Analyst Commentary Recent research on AbbVie highlights a split view, with some analysts focusing on the upside from the immunology pipeline and operating leverage, while others point to valuation and competitive questions after a period of share underperformance.Mise à jour du récit • Mar 24
ABBV: Future Returns Will Hinge On Immunology Encore Outweighing Competitive Concerns
Narrative Update The analyst price target for AbbVie has been adjusted slightly higher to reflect a fair value move to about $249. Analysts point to early stage indication expansion, operating leverage potential, and ongoing immunology pipeline developments, even as some firms flag emerging competition and a more balanced risk and reward profile.Mise à jour du récit • Mar 10
ABBV: Future Returns Will Depend On Immunology Encore And Deal Optionality Uncertainty
The analyst price target for AbbVie edges higher to align with our fair value shift from $248.29 to $248.86, as analysts highlight ongoing indication expansion in immunology, potential operating leverage, and multiple expansion drivers, even as some firms note emerging competition and a more balanced risk and reward profile. Analyst Commentary Recent research on AbbVie reflects a split view, with some analysts pointing to upside tied to immunology growth and pipeline execution, while others flag competition risk and a more balanced risk and reward profile at current levels.Mise à jour du récit • Feb 22
ABBV: Future Returns Will Rely On Immunology Encore And Evolving Deal Optionality
Our updated AbbVie narrative reflects a modest price target increase to about $248 per share, as analysts point to potential operating leverage, room for P/E multiple expansion, and a pipeline of proof-of-concept and immunology programs that could support slightly higher revenue growth assumptions, even as margin expectations are trimmed. Analyst Commentary Recent research shows a mix of optimism and caution around AbbVie, with several firms adjusting price targets and ratings as they reassess execution risks, competitive pressures, and the potential impact of the pipeline on valuation.Mise à jour du récit • Feb 07
ABBV: Future Returns Will Depend On Immunology Pipeline Clarity And M&A Uncertainty
Analysts have trimmed their price targets for AbbVie by a small amount. This reflects slightly lower revenue growth and P/E assumptions, while also incorporating a modestly higher profit margin and recent mixed research views around competition and pipeline visibility.Mise à jour du récit • Jan 24
ABBV: Future Returns Will Hinge On Post-Humira Immunology And Deal Optionality
Analysts have nudged their price target for AbbVie slightly higher to reflect a fair value estimate of about $245 per share, supported by updated assumptions for revenue growth, profit margins, and a modestly lower future P/E. Recent research highlights both increased price targets and more cautious views around competition and the sustainability of outperformance in key immunology drugs.Mise à jour du récit • Jan 09
ABBV: Future Returns Will Depend On Post-Humira Immunology And Pipeline Execution
Analysts have trimmed their AbbVie fair value estimate by about $0.10 per share to roughly $244.56. This reflects a mix of slightly higher risk assumptions, modestly adjusted revenue and margin expectations, and a more balanced set of views after recent downgrades and price target changes that suggest outperformance is already well reflected in the current share price.Article d’analyse • Jan 08
AbbVie's (NYSE:ABBV) Dividend Will Be Increased To $1.73
AbbVie Inc. ( NYSE:ABBV ) will increase its dividend from last year's comparable payment on the 17th of February to...Mise à jour du récit • Dec 21
ABBV: Future Returns Will Hinge On Post-Humira Immunology And Pipeline Execution
Analysts have nudged our AbbVie fair value estimate slightly higher, from $243.55 to $244.68. This reflects modestly stronger long term revenue growth expectations for key immunology franchises and pipeline assets, partially offset by slightly lower margin assumptions and a broadly constructive but mixed backdrop of recent price target revisions and rating changes across the Street.Mise à jour du récit • Dec 07
ABBV: Future Performance Will Depend On Extended Exclusivity And Pipeline Execution
Analysts have nudged their average price target on AbbVie modestly higher to reflect a wave of target increases into the mid 240s to low 260s dollar range, supported by stronger visibility into Skyrizi and Rinvoq driven growth, extended Rinvoq exclusivity, and a more favorable large cap biopharma backdrop despite mixed ratings changes. Analyst Commentary Recent research paints a generally constructive picture on AbbVie, with most price target revisions skewing higher even as some firms move to the sidelines.Article d’analyse • Dec 02
AbbVie (NYSE:ABBV) Is Increasing Its Dividend To $1.73
The board of AbbVie Inc. ( NYSE:ABBV ) has announced that it will be paying its dividend of $1.73 on the 17th of...Mise à jour du récit • Nov 23
ABBV: Future Performance Will Depend On Pipeline Expansion And Patent Protections
AbbVie’s analyst price target has increased modestly from $241.29 to $243.55. Analysts cite resilient performance in immunology products, extended Rinvoq exclusivity, and improving fundamentals as key drivers of sentiment.Article d’analyse • Nov 18
AbbVie's (NYSE:ABBV) Dividend Will Be Increased To $1.73
The board of AbbVie Inc. ( NYSE:ABBV ) has announced that it will be paying its dividend of $1.73 on the 17th of...Mise à jour du récit • Nov 08
ABBV: Future Performance Will Reflect Balance Between Patent Wins and Product Pressures
AbbVie's analyst price target has risen modestly from $237.48 to $241.29. Analysts cite resilient fundamentals and long-term patent settlements, which help offset recent industry downgrades and softer performance in some business units.Ventilation des recettes et des dépenses
Ventilation des recettes et des dépenses
Comment AbbVie gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 31 Mar 26 | 62,819 | 3,595 | 13,918 | 9,473 |
| 31 Dec 25 | 61,160 | 4,186 | 13,644 | 9,068 |
| 30 Sep 25 | 59,644 | 2,348 | 12,601 | 8,787 |
| 30 Jun 25 | 58,328 | 3,723 | 13,215 | 8,568 |
| 31 Mar 25 | 57,367 | 4,155 | 14,256 | 8,385 |
| 31 Dec 24 | 56,334 | 4,238 | 14,099 | 8,131 |
| 30 Sep 24 | 55,533 | 5,081 | 13,968 | 7,755 |
| 30 Jun 24 | 55,000 | 5,298 | 13,193 | 7,405 |
| 31 Mar 24 | 54,403 | 5,951 | 13,032 | 7,189 |
| 31 Dec 23 | 54,318 | 4,820 | 12,419 | 7,038 |
| 30 Sep 23 | 55,138 | 6,471 | 12,453 | 6,897 |
| 30 Jun 23 | 56,023 | 8,635 | 12,260 | 6,785 |
| 31 Mar 23 | 56,741 | 7,535 | 12,201 | 6,661 |
| 31 Dec 22 | 58,054 | 11,782 | 14,584 | 6,487 |
| 30 Sep 22 | 57,819 | 13,343 | 12,116 | 6,518 |
| 30 Jun 22 | 57,349 | 12,569 | 11,988 | 6,551 |
| 31 Mar 22 | 56,725 | 12,407 | 11,943 | 6,692 |
| 31 Dec 21 | 56,197 | 11,468 | 11,872 | 6,820 |
| 30 Sep 21 | 55,169 | 7,465 | 11,054 | 6,829 |
| 30 Jun 21 | 53,729 | 6,599 | 10,860 | 6,761 |
| 31 Mar 21 | 50,195 | 5,092 | 10,955 | 6,418 |
| 31 Dec 20 | 45,804 | 4,556 | 9,867 | 6,003 |
| 30 Sep 20 | 40,650 | 7,324 | 9,429 | 5,902 |
| 30 Jun 20 | 36,227 | 6,906 | 8,288 | 5,582 |
| 31 Mar 20 | 34,057 | 8,395 | 6,760 | 5,467 |
| 31 Dec 19 | 33,266 | 7,842 | 6,763 | 5,377 |
| 30 Sep 19 | 32,867 | 3,232 | 6,487 | 5,260 |
| 30 Jun 19 | 32,624 | 4,093 | 6,765 | 5,273 |
| 31 Mar 19 | 32,647 | 5,333 | 6,873 | 5,304 |
| 31 Dec 18 | 32,753 | 5,657 | 7,353 | 5,259 |
| 30 Sep 18 | 32,187 | 7,531 | 6,972 | 5,242 |
| 30 Jun 18 | 30,946 | 6,419 | 6,623 | 5,202 |
| 31 Mar 18 | 29,612 | 6,352 | 6,303 | 5,109 |
| 31 Dec 17 | 28,216 | 5,283 | 6,248 | 5,007 |
| 30 Sep 17 | 27,273 | 6,615 | 5,958 | 4,789 |
| 30 Jun 17 | 26,710 | 6,582 | 5,799 | 4,667 |
| 31 Mar 17 | 26,218 | 6,278 | 5,861 | 4,562 |
| 31 Dec 16 | 25,638 | 5,923 | 5,837 | 4,385 |
| 30 Sep 16 | 25,242 | 6,048 | 5,733 | 4,178 |
| 30 Jun 16 | 24,754 | 5,690 | 5,724 | 4,472 |
| 31 Mar 16 | 23,777 | 5,448 | 5,646 | 4,236 |
| 31 Dec 15 | 22,859 | 5,118 | 5,663 | 4,101 |
| 30 Sep 15 | 21,911 | 2,790 | 6,059 | 3,978 |
Des revenus de qualité: ABBV a un important ponctuel perte de $13.6B impactant ses 12 derniers mois de résultats financiers à 31st March, 2026.
Augmentation de la marge bénéficiaire: Les marges bénéficiaires nettes actuelles de ABBV sont inférieures à celles de l'année dernière ABBV. (5.7%) sont inférieures à celles de l'année dernière (7.2%).
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: Les bénéfices de ABBV ont diminué de 21% par an au cours des 5 dernières années.
Accélération de la croissance: ABBV a connu une croissance négative de ses bénéfices au cours de l'année écoulée, elle ne peut donc pas être comparée à sa moyenne sur 5 ans.
Bénéfices par rapport au secteur d'activité: ABBV a enregistré une croissance négative de ses bénéfices ( -13.5% ) au cours de l'année écoulée, ce qui rend difficile la comparaison avec la moyenne du secteur Biotechs ( 59.3% ).
Rendement des fonds propres
ROE élevé: Le passif ABBV dépasse son actif, il est donc difficile de calculer son rendement des capitaux propres.
Rendement des actifs
Rendement des capitaux employés
Découvrir des entreprises performantes dans le passé
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/07/24 22:10 |
| Cours de l'action en fin de journée | 2026/07/24 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
AbbVie Inc. est couverte par 51 analystes. 25 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| David Toung | Argus Research Company |
| Emily Field | Barclays |
| Luisa Hector | Berenberg |